Unresectable Colorectal Cancer

• CLINICAL_TRIALS research · 2026-04-21
  Clinical Trial Update: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation [Phase 2]

  A Phase 2 trial evaluating adding nivolumab to standard therapy for patients with metastatic or unresectable colorectal cancer with a BRAF m…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer [Phase 1]

  A Phase 1 clinical trial is evaluating Emavusertib (CA-4948) in combination with FOLFOX chemotherapy plus Bevacizumab for metastatic colorec…

• CLINICAL_TRIALS research · 2026-01-22
  Clinical Trial Update: SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial [Phase 1, Phase 2]

  Clinical STOPTRAFFIC-1 trial evaluates SX-682 in combination with Nivolumab for RAS-mutated, MSS unresectable or metastatic colorectal cance…

• CLINICAL_TRIALS research · 2025-12-23
  Clinical Trial Update: LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer [Phase 1, Phase 2]

  This clinical trial update covers a Phase 1/2 study evaluating LY3214996 with cetuximab, alone or in combination with abemaciclib, for unres…

• CLINICAL_TRIALS trial_result · 2025-11-20
  Clinical Trial Update: Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer [Phase 1, Phase 2]

  A Phase 1/2 clinical trial is evaluating a triple combination of encorafenib, cetuximab, and nivolumab in patients with microsatellite-stabl…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2024-09-26
  Clinical Trial Update: Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) [Phase 2]

  A Phase 2 trial of pembrolizumab with autologous dendritic cells for refractory colorectal cancer has been withdrawn.

• CLINICAL_TRIALS trial_result · 2024-05-21
  Clinical Trial Update: Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer [Phase 2]

  Phase 2 clinical trial update evaluating panitumumab, regorafenib, and TAS-102 in patients with metastatic and/or unresectable RAS wild-type…